Jerome I Rotter, MD
Investigator, The Lundquist Institute
Director, Institute for Translational Genomics and Population Sciences, The Lundquist Institute
Director, Division of Genomic Outcomes, Departments of Pediatrics and Medicine, Harbor-UCLA Medical Center
Professor of Pediatrics and Human Genetics, UCLA
Genetic basis of common diseases, genome-wide association and sequencing studies.
Research DescriptionDr. Rotter is a pioneer in the field of medical genetics, genetic epidemiology, and personalized medicine. He has engaged in the study of the genetic epidemiology of chronic common diseases for over 4 decades, with an emphasis on cardiovascular/metabolic diseases (coronary artery disease, dyslipidemia, hypertension, type 2 diabetes, insulin resistance, obesity, fatty liver, arrhythmias), gastrointestinal/autoimmune disorders (type 1 diabetes, inflammatory bowel disease, coeliac disease), ocular disorders (keratoconus, diabetic retinopathy, glaucoma), and pharmacogenetic studies. His studies have included family based, case control, cohort, and pharmacogenetic designs; have included different ethnic groups (Caucasian, Hispanics, African-Americans, Chinese, Ashkenazi Jews, and Armenians); and have ranged from linkage, candidate gene, genome-wide association (GWA) and post-GWA studies, and now whole exome and whole genome sequencing studies, and multi-omics studies (methylomics, transcriptomics, metabolomics). The ultimate goal of this work is to identify the optimal therapy and prevention for cardiometabolic and ocular disorders as a function of an individual’s genetic predisposition. Thus, this is the basis for precision/personalized medicine, especially in minority populations.
- BA, 1970, University of California, Los Angeles
- MD, 1973, University of California, Los Angeles
Recent and/or Significant Publications
Qi Q, Stilp AM, Sofer T, Moon J-Y, Hidalgo B, Szpiro AA, Ng MC, MEDIA Consortium, Chen Y-DI, Taylor KD, Aviles-Santa ML, Papanicolaou G, Pankow J, Schneiderman N, Laurie CC, Rotter JI, Kaplan RC. Genetics of diabetes in U.S. Hispanic/Latino individuals: results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), Diabetes, 66(5):1419-1425, May, 2017. (e-published 3/2/2017, doi:10.2337/db16-1150) PMID: 28254843 PMCID: 5399610
Dewey FE, Gusarova V, Dunbar RL, Guo X, Rotter JI, Chen Y-DI, Mellis SJ, Gromada J, Baras A. Genetic and pharmacologic inactivation of ANGPTL3 and atherosclerotic cardiovascular disease, New England Journal of Medicine, 377(3):211, July 20, 2017. (e-published 5/24/2017, doi:10.1056/NEJMoa1612790) PMID: 28538136
Zhao W, Rasheed A, Tikkanen E, et al. Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nat Genet. 2017;49(10):1450–1457. doi:10.1038/ng.3943
Wheeler E, Leong A, Liu CT, et al. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Med. 2017;14(9):e1002383. Published 2017 Sep 12. doi:10.1371/journal.pmed.1002383
Richard MA, Huan T, Ligthart S, et al. DNA Methylation Analysis Identifies Loci for Blood Pressure Regulation. Am J Hum Genet. 2017;101(6):888–902. doi:10.1016/j.ajhg.2017.09.028